Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 8/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607082 | 0.84 | CCR3 (0.55) | CCR3CYP2D6 | |
| SCHEMBL4605023 | 0.84 | CCR3 (0.57) | KMT2ACCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4900580 | 0.78 | CNR1 (0.60) | KMT2AFPR2CNR1CCR3SLC6A3 | |
| SCHEMBL4604725 | 0.72 | CHEK1 (0.45) | KMT2ACNR1CCR3SLC6A3MAPT | |
| SCHEMBL4604479 | 0.72 | SLC6A3 (0.48) | KMT2AFPR2CNR1SLC6A3RAB9A | |
| SCHEMBL8122584 | 0.70 | KMT2A (0.57) | KMT2AFPR2CNR1RAB9ANPC1 | |
| SCHEMBL4604891 | 0.70 | CCR3 (0.69) | CCR3CYP2D6 | |
| SCHEMBL4881257 | 0.70 | HDAC3 (0.49) | KMT2ACCR3RAB9ANPC1MAPT | |
| SCHEMBL4891370 | 0.70 | KMT2A (0.45) | KMT2AFPR2CNR1RAB9ANPC1 | |
| SCHEMBL4607257 | 0.69 | CCR3 (0.50) | KMT2ACCR3PRMT3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | KMT2A 4826/4885FPR2 45/4885CNR1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.